Zoetis ( (ZTS) ) has released its Q3 earnings. Here is a breakdown of the information Zoetis presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zoetis Inc., a leading animal health company, specializes in providing medicines, vaccines, diagnostics, and technologies for veterinarians, pet owners, and livestock producers globally. In its third quarter of 2025, Zoetis reported a revenue increase of 1% to $2.4 billion and a net income rise of 6% to $721 million, showcasing a steady financial performance. The company achieved 4% organic operational growth in revenue and 9% in adjusted net income, reflecting disciplined execution and strategic advancements.
Key financial highlights include adjusted net income of $754 million and adjusted diluted earnings per share of $1.70. Zoetis also revised its full-year 2025 revenue guidance to $9.400 – $9.475 billion, with expectations of 5.5% to 6.5% organic operational revenue growth. The company maintained its guidance for adjusted diluted EPS between $6.30 and $6.40, demonstrating confidence in its operational strategies.
Zoetis continues to innovate with significant product approvals and geographic expansions, including new monoclonal antibody therapies for osteoarthritis pain in pets and expanded parasiticide offerings. The company also enhanced its diagnostics capabilities and livestock product portfolio, emphasizing its commitment to advancing animal care and addressing unmet market needs.
Looking ahead, Zoetis remains focused on leveraging its strong customer relationships, robust pipeline, and manufacturing excellence to drive sustainable growth and value for shareholders. The company anticipates continued success with new product launches and strategic initiatives aimed at reinforcing its market leadership.